Present work describes a precise, accurate and reproducible stability indicating Reverse phase High Performance Liquid Chromatographic (RP-HPLC) method for simultaneous estimation of Escitalopram Oxalate and Clonazepam on Kromasil 100 C18, 5µ (150×4.6 mm) column using Methanol: 0.025 M KH2PO4 Buffer (45:55 v/v) pH 3.0 adjusted with o-phosphoric acid as mobile phase at a flow rate of 1.0 ml/min and the detection wavelength was 254 nm. The retention time for ESC and CLO was found to be 6.8 and 12.7 min, respectively. The method was validated for linearity, precision, accuracy, robustness, solution stability and specificity. The method was linear in the concentration range of 20-140µg/ml for ESC and 2-14 µg/ml for CLO with a correlation coefficient of 0.999 and 0.999 for respective drugs. The % RSD for intra-day precision was found to be in the range of 0.28-0.54 and 0.34 -0.58; while inter-day precision was found to be in the range of 0.36-0.97 and 0.46-0.75 for ESC and CLO, respectively. The percent recovery was found in the range of 99.23-101.96 % and 99.42-101.96 % for ESC and CLO, respectively. The specificity of HPLC method was confirmed by performing forced degradation study of ESC and CLO under thermal, humidity, acidic, alkaline, neutral, oxidative and photolytic conditions. Escitalopram degraded significantly in basic condition, while clonazepam degraded significantly under acidic, alkaline, oxidative, thermal & humidity conditions and marginally in thermal condition. The developed RP-HPLC method adequately separated the drug from the degradation products proving the specificity of method and can be used for stability analysis.
Loading....